Sagimet Biosciences
SGMT
72 hedge funds and large institutions have $86.7M invested in Sagimet Biosciences in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 14 closing their positions.
112% more call options, than puts
Call options by funds: $2.85M | Put options by funds: $1.34M
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
7% more funds holding
Funds holding: 67 → 72 (+5)
2.69% more ownership
Funds ownership: 38.06% → 40.76% (+2.7%)
3% less capital invested
Capital invested by funds: $89M → $86.7M (-$2.31M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.68M |
| 2 |
D.E. Shaw & Co
New York
|
+$4.52M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.49M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$2.84M |
| 5 |
Renaissance Technologies
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$8.52M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.16M |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$1.13M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$918K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$883K |
SGMT Hedge Fund Activity: Q3 2025 in Review
72 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q3 2025, worth a combined $86.7M — down 2.6% from $89M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SGMT positions and 14 closed out — a net gain of 6 holders — while 21 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.68M. The largest seller was Woodline Partners, cutting an estimated $8.52M.
- 72 institutional investors held Sagimet Biosciences (SGMT) as of Q3 2025, up from 67 in Q2 2025.
- Funds reported $86.7M of Sagimet Biosciences stock for Q3 2025, down 2.6% quarter-over-quarter.
- 20 funds opened new Sagimet Biosciences positions in Q3 2025 and 14 closed out, a net change of +6 holders.
- The largest Sagimet Biosciences buyer in Q3 2025 was Millennium Management, an estimated $5.68M added.
- The largest Sagimet Biosciences seller in Q3 2025 was Woodline Partners, an estimated $8.52M sold.
Based on aggregated 13F filings for Q3 2025.